Q1 EPS Forecast for Outlook Therapeutics Lowered by Analyst

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Investment analysts at Brookline Capital Management reduced their Q1 2025 earnings per share estimates for shares of Outlook Therapeutics in a note issued to investors on Monday, December 30th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.70) per share for the quarter, down from their prior estimate of ($0.62). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($2.00) EPS and FY2027 earnings at $1.26 EPS.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.06.

Several other analysts have also commented on OTLK. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a report on Friday, November 29th. BTIG Research dropped their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 29th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.73.

Outlook Therapeutics Price Performance

Shares of Outlook Therapeutics stock opened at $2.06 on Wednesday. The stock has a market cap of $51.31 million, a PE ratio of -0.19 and a beta of 0.46. The firm has a fifty day moving average price of $3.53 and a 200 day moving average price of $5.74. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new stake in shares of Outlook Therapeutics during the second quarter worth $75,000. Christensen King & Associates Investment Services Inc. purchased a new stake in Outlook Therapeutics during the 3rd quarter valued at about $55,000. Barclays PLC raised its holdings in Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after acquiring an additional 18,249 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Outlook Therapeutics in the 2nd quarter worth approximately $232,000. Finally, XTX Topco Ltd acquired a new position in shares of Outlook Therapeutics during the 3rd quarter worth approximately $199,000. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.